FDA Official to Exit Amid Drug Approval Concerns & Industry Criticism

Washington D.C. – Dr. Vinay Prasad, the U.S. Food and Drug Administration’s (FDA) director of the Center for Biologics Evaluation and Research, will step down from his position at the end of April, marking a period of significant upheaval and controversy within the agency. This is Prasad’s second departure from the role; he briefly left in July 2025 before returning weeks later, and his exit comes amid mounting criticism of the FDA’s recent drug and vaccine approval processes.

The departure, first reported by the Wall Street Journal, follows a year of increasingly fraught decisions by the FDA, including initial resistance to reviewing Moderna’s mRNA-based flu vaccine application – a decision later reversed with adjustments – and challenges to data submitted by companies developing treatments for serious conditions. FDA Commissioner Dr. Marty Makary stated on social media that a successor will be appointed before Prasad returns to his teaching position at the University of California, San Francisco.

The agency’s recent actions have sparked concern within the biotechnology and pharmaceutical industries, with at least eight drug applications facing denial or discouragement in the past year, according to investment firm RTW Investments. The core of the industry’s complaint centers on perceived inconsistencies in the FDA’s regulatory approach. Companies allege that the agency is shifting its expectations for the evidence required to support drug applications, creating a climate of uncertainty and potentially hindering the development of treatments for difficult-to-treat diseases.

The controversy surrounding UniQure’s gene therapy for Huntington’s disease has been particularly acute. The FDA, in a rare move, convened a media call to defend its request for additional trial data and to address criticism of its handling of the application. This defensive posture reflects a broader trend of increased scrutiny and, according to some observers, a more cautious approach to approvals under the current administration.

A former FDA official, speaking anonymously to CNBC, described the situation as the “worst kind of regulatory uncertainty,” explaining that companies are being told one thing and then experiencing another. The FDA itself maintains that its decisions are based solely on the available evidence, stating in a recent communication that it conducts “rigorous, independent reviews and not rubber-stamping approvals.”

Prasad’s tenure was marked by a willingness to challenge established norms and question the evidence supporting certain drug approvals. As a professor at UCSF, he was a vocal critic of the government’s Covid-19 response and previously criticized his predecessor, Dr. Peter Marks, for approving medicines he believed lacked sufficient supporting data. This independent streak, while lauded by some, appears to have contributed to the friction within the agency and with industry stakeholders.

The FDA has also undergone significant internal changes recently, including staff cuts and an overhaul initiated by Health and Human Services Secretary Robert F. Kennedy Jr. These changes, coupled with the agency’s more assertive stance on drug approvals, have fueled concerns that the FDA may be stifling innovation and potentially jeopardizing patient access to new treatments. These concerns were amplified at a recent CNBC Cures event, where industry leaders voiced their anxieties about the evolving regulatory landscape.

The situation was further complicated by comments made by Dr. Makary himself during a CNBC interview with Becky Quick, where he appeared to critique UniQure’s Huntington’s disease treatment. This public questioning of a specific therapy added to the perception of a shifting and unpredictable regulatory environment.

Prasad’s initial departure in July 2025 followed backlash over his regulatory decisions and accusations of political bias from figures like Laura Loomer, who alleged he was aligned with liberal ideologies and held a negative view of President Donald Trump. While the circumstances surrounding his return in August were not fully disclosed, his ultimate decision to leave the agency again underscores the challenges of navigating the complex political and scientific pressures inherent in the role of FDA director.

The FDA’s evolving approach to drug and vaccine approvals is likely to have significant implications for the biotechnology and pharmaceutical industries, potentially impacting investment decisions, research and development priorities, and the availability of new treatments for patients. The appointment of Prasad’s successor will be closely watched by industry observers, who will be looking for signals about the agency’s future direction and its commitment to fostering innovation while ensuring patient safety.